Precision Medicine Fuels Familial Hypercholesterolemia Market Growth

New York, Thursday, 27 November 2025.
From 2025 to 2035, advancements in precision medicine are set to significantly boost the familial hypercholesterolemia market, driven by personalized treatments and genetic screenings. Key players like Regeneron and Novartis are leading innovations.